138 results on '"Carson, III, William E."'
Search Results
2. Targeting metabolic sensing switch GPR84 on macrophages for cancer immunotherapy
3. Targeting Myeloid-Derived Suppressor Cells via Dual-Antibody Fluorescent Nanodiamond Conjugate.
4. Fluctuations in depression and anxiety predict dysregulated leptin among obese breast cancer survivors
5. An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer.
6. Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy
7. Roles of Androgen Receptor Signaling in Urothelial Carcinoma.
8. An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck
9. Soy-tomato enriched diet reduces inflammation and disease severity in a pre-clinical model of chronic pancreatitis
10. Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer
11. Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer.
12. Dual IL-6 and CTLA-4 blockade regresses pancreatic tumors in a T cell and CXCR3-dependent manner
13. Generation of monocyte-derived tumor-associated macrophages using tumor-conditioned media provides a novel method to study tumor-associated macrophages in vitro
14. Soy isoflavones and their metabolites modulate cytokine-induced natural killer cell function
15. Synergy from gene expression and network mining (SynGeNet) method predicts synergistic drug combinations for diverse melanoma genomic subtypes
16. Depression, Inflammation, and Intestinal Permeability: Associations with Subjective and Objective Cognitive Functioning throughout Breast Cancer Survivorship.
17. Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer
18. Classification of Indeterminate Melanocytic Lesions by MicroRNA Profiling
19. A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas
20. Expression of microRNAs and their target genes in melanomas originating from gynecologic sites.
21. A Comprehensive Program for the Enhancement of Accrual to Clinical Trials
22. Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease
23. Myeloid-derived suppressor cells in breast cancer
24. Enhanced anti-tumor activity of interferon-alpha in SOCS1-deficient mice is mediated by CD4+ and CD8+ T cells
25. Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4+ T cells from patients with GI malignancy
26. Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells
27. A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab
28. Immune, endocrine, and behavioral precursors to breast cancer recurrence: a case-control analysis
29. Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assay
30. STAT1-dependent and STAT1-independent gene expression in murine immune cells following stimulation with interferon-alpha
31. A Randomized Phase 2 Trial of Bevacizumab with or without Daily Low-Dose Interferon Alfa-2b in Metastatic Malignant Melanoma
32. Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy
33. Release of Biologically Functional Interferon-Alpha from a Nanochannel Delivery System
34. Patterns of Recurrence After Sentinel Lymph Node Biopsy for Breast Cancer
35. Chapter 21 - Natural Killer Cell Immunity AND THERAPY
36. Understanding Interferon: Translating Biologic Advances into Clinical Progress
37. CD200 promotes immunosuppression in the pancreatic tumor microenvironment
38. Loss of miR-1469 expression mediates melanoma cell migration and invasion.
39. The Role of Myeloid Derived Suppressor Cells in Urothelial Carcinoma Immunotherapy
40. Antibody Conjugation of Fluorescent Nanodiamonds for Targeted Innate Immune Cell Activation.
41. Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy
42. Generation of monocyte-derived tumorassociated macrophages using tumorconditioned media provides a novel method to study tumor-associated macrophages in vitro.
43. Extended Follow up of a Phase 2 Study of Early Intervention with Lenalidomide in Patients with High-Risk Chronic Lymphocytic Leukemia
44. Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors.
45. Impact of breast cancer recurrence and cancer-specific stress on spouse health and immune function
46. MiR-21 Enhances Melanoma Invasiveness via Inhibition of Tissue Inhibitor of Metalloproteinases 3 Expression: In Vivo Effects of MiR-21 Inhibitor
47. Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma.
48. Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.
49. Inflammatory Cytokines and Comorbidity Development in Breast Cancer Survivors Versus Noncancer Controls: Evidence for Accelerated Aging?
50. Plasma MicroRNA Levels Following Resection of Metastatic Melanoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.